The Lancet

Medications

Budesonide yields durable reduction in eGFR for IgA nephropathy

For patients with immunoglobulin A (IgA) nephropathy, nine months of treatment with targeted-release formulation of budesonide (Nefecon) yields a greater reduction in estimated glomerular filtration rate (eGFR) than placebo, ...

Addiction

Q&A: Bringing addiction care 'inside the house of medicine'

As civilization ground to a halt during the COVID-19 pandemic, trapping humans like caged mice, addiction expert Keith Humphreys could only agonize over the collateral damage. America was already losing the war on addiction ...

Diseases, Conditions, Syndromes

Raising awareness of long COVID 'blue legs' symptom

An unusual case of a long COVID patient's legs turning blue after 10 minutes of standing highlights the need for greater awareness of this symptom among people with the condition, according to new research. The study, "Venous ...

page 12 from 40